Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: A randomized controlled trial

American Journal of Kidney Diseases

Volumn 59, Issue 1, 2012, Pages 58-66

  Kovesdy, Csaba P ^a,b   Lu, Jun L ^c   Malakauskas, Sandra M ^a,b   Andress, Dennis L ^d   Kalantar Zadeh, Kamyar ^e,f   Ahmadzadeh, Shahram ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Salem Research Institute   (United States)

^d ABBOTT LABORATORIES   (United States)

^e UCLA MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

clinical trial; ergocalciferol; Parathyroid hormone; paricalcitol; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ERGOCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL;

AGED; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; VITAMINS;

EID: 83655191998     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.06.027     Document Type: Article

References (46)

1. A. Levin, G.L. Bakris, M. Molitch Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease Kidney Int 71 2007 31 38
2. K. Kalantar-Zadeh, N. Kuwae, D.L. Regidor Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients Kidney Int 70 2006 771 780
3. S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, F.K. Port Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 2001 2131 2138
4. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2004 2208 2218
5. K. Kalantar-Zadeh, A. Shah, U. Duong, R.C. Hechter, R. Dukkipati, C.P. Kovesdy Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals Kidney Int Suppl 2010 S10 S21
6. C.P. Kovesdy, S. Ahmadzadeh, J.E. Anderson, K. Kalantar-Zadeh Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease Kidney Int 73 2008 1296 1302
7. C.P. Kovesdy, K. Kalantar-Zadeh Bone and mineral disorders in pre-dialysis CKD Int Urol Nephrol 40 2008 427 440
8. N.S. Bricker On the pathogenesis of the uremic state An exposition of the "trade-off hypothesis." N Engl J Med 286 1972 1093 1099
9. F. Llach, S.G. Massry On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency J Clin Endocrinol Metab 61 1985 601 606
10. T.O. Pitts, B.H. Piraino, R. Mitro Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure J Clin Endocrinol Metab 67 1988 876 881
11. J.A. Delmez, C. Tindira, P. Grooms, A. Dusso, D.W. Windus, E. Slatopolsky Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D A role for increased sensitivity to calcium J Clin Invest 83 1989 1349 1355
12. A.A. Ginde, M.C. Liu, C.A. Camargo Jr Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004 Arch Intern Med 169 2009 626 632
13. M. Wolf, A. Shah, O. Gutierrez Vitamin D levels and early mortality among incident hemodialysis patients Kidney Int 72 2007 1004 1013
14. P. Lips, A. Wiersinga, F.C. van Ginkel The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects J Clin Endocrinol Metab 67 1988 644 650
15. O. Gutierrez, T. Isakova, E. Rhee Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease J Am Soc Nephrol 16 2005 2205 2215
16. A.A. Portale, B.E. Booth, H.C. Tsai, R.C. Morris Jr Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency Kidney Int 21 1982 627 632
17. L.R. Baker, L. Abrams, C.J. Roe 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial Kidney Int 35 1989 661 669
18. C.P. Kovesdy, R. Mehrotra, K. Kalantar-Zadeh Battleground: chronic kidney disorders mineral and bone diseasecalcium obsession, vitamin D, and binder confusion Clin J Am Soc Nephrol 3 2008 168 173
19. J.M. Frazao, L. Elangovan, H.M. Maung Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism Am J Kidney Dis 36 2000 550 561
20. K.J. Martin, E.A. Gonzalez, M. Gellens, L.L. Hamm, H. Abboud, J. Lindberg 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis J Am Soc Nephrol 9 1998 1427 1432
21. J.J. Kazama, H. Maruyama, I. Narita, F. Gejyo Maxacalcitol is a possible less phosphatemic vitamin D analog Ther Apher Dial 9 2005 352 354
22. C.P. Kovesdy, K. Kalantar-Zadeh Vitamin D receptor activation and survival in chronic kidney disease Kidney Int 73 2008 1355 1363
23. C.P. Kovesdy Survival benefits with vitamin D receptor activation: new insights since 2003 Clin J Am Soc Nephrol 5 2010 1704 1709
24. P.H. Anderson, B.K. May, H.A. Morris Vitamin D metabolism: new concepts and clinical implications Clin Biochem Rev 24 2003 13 26
25. K. Kalantar-Zadeh, C.P. Kovesdy Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease Clin J Am Soc Nephrol 4 2009 1529 1539
26. G. Eknoyan, A. Levin, N. Levin Bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 2003 1 201
27. R.B. Payne, A.J. Little, R.B. Williams, J.R. Milner Interpretation of serum calcium in patients with abnormal serum proteins Br Med J 4 1973 643 646
28. A.B. Korkor Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure N Engl J Med 316 1987 1573 1577
29. M.L. Melamed, J.A. Eustace, L. Plantinga Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study Kidney Int 70 2006 351 357
30. M. Naves-Diaz, D. Alvarez-Hernandez, J. Passlick-Deetjen Oral active vitamin D is associated with improved survival in hemodialysis patients Kidney Int 74 2008 1070 1078
31. C.S. Shinaberger, J.D. Kopple, C.P. Kovesdy Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients Clin J Am Soc Nephrol 3 2008 1769 1776
32. T. Shoji, K. Shinohara, E. Kimoto Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population Nephrol Dial Transplant 19 2004 179 184
33. M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J.M. Lazarus, R. Thadhani Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy N Engl J Med 349 2003 446 456
34. M. Teng, M. Wolf, M.N. Ofsthun Activated injectable vitamin D and hemodialysis survival: a historical cohort study J Am Soc Nephrol 16 2005 1115 1125
35. F. Tentori, W.C. Hunt, C.A. Stidley Mortality risk among hemodialysis patients receiving different vitamin D analogs Kidney Int 70 2006 1858 1865
36. F. Tentori, J.M. Albert, E.W. Young The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study Nephrol Dial Transplant 24 2009 963 972
37. C.P. Kovesdy, S. Ahmadzadeh, J.E. Anderson, K. Kalantar-Zadeh Association of activated vitamin D treatment and mortality in chronic kidney disease Arch Intern Med 168 2008 397 403
38. A.B. Shoben, K.D. Rudser, I.H. de Boer, B. Young, B. Kestenbaum Association of oral calcitriol with improved survival in nondialyzed CKD J Am Soc Nephrol 19 2008 1613 1619
39. P. Kandula, M. Dobre, J.D. Schold, M.J. Schreiber Jr, R. Mehrotra, S.D. Navaneethan Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials Clin J Am Soc Nephrol 6 2011 50 62
40. D.W. Coyne Vitamin D compounds in chronic kidney disease Ann Intern Med 148 2008 969 970
41. S.C. Palmer, D.O. McGregor, P. Macaskill, J.C. Craig, G.J. Elder, G.F. Strippoli Meta-analysis: vitamin D compounds in chronic kidney disease Ann Intern Med 147 2007 840 853
42. S.M. Moe, A. Saifullah, R.E. LaClair, S.A. Usman, Z. Yu A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease Clin J Am Soc Nephrol 5 2010 299 306
43. C.P. Kovesdy, V. Ureche, J.L. Lu, K. Kalantar-Zadeh Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD Nephrol Dial Transplant 25 2010 3003 3011
44. D.L. Regidor, C.P. Kovesdy, R. Mehrotra Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients J Am Soc Nephrol 19 2008 2193 2203
45. 3 on serum calcium and phosphorus in hemodialysis patients Am J Kidney Dis 40 2002 1283 1288
46. S.M. Sprague, F. Llach, M. Amdahl, C. Taccetta, D. Batlle Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism Kidney Int 63 2003 1483 1490